Cover Image

Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: systematic review and meta-analysis of randomized trials

Background & aims - Inflammation plays a key role in tumor development and progression. Vitamin D has potential tumor suppressing effects through modulation of inflammatory processes. The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) was to summarize and...

Full description

Saved in:
Bibliographic Details
Main Authors: Gwenzi, Tafirenyika (Author) , Zhu, Anna (Author) , Schrotz-King, Petra (Author) , Schöttker, Ben (Author) , Hoffmeister, Michael (Author) , Brenner, Hermann (Author)
Format: Article (Journal)
Language:English
Published: July 2023
In: Clinical nutrition
Year: 2023, Volume: 42, Issue: 7, Pages: 1142-1150
ISSN:1532-1983
DOI:10.1016/j.clnu.2023.05.009
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.clnu.2023.05.009
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0261561423001516
Get full text
Author Notes:Tafirenyika Gwenzi, Anna Zhu, Petra Schrotz-King, Ben Schöttker, Michael Hoffmeister, Hermann Brenner
Description
Summary:Background & aims - Inflammation plays a key role in tumor development and progression. Vitamin D has potential tumor suppressing effects through modulation of inflammatory processes. The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) was to summarize and evaluate the effects of vitamin D3 supplementation (VID3S) on serum inflammatory biomarkers among patients with cancer or pre-cancerous lesions. - Methods - We searched PubMed, Web of Science and Cochrane databases until November 2022. The effects of VID3S were estimated from pooled standardized mean differences (SMDs) with their 95% confidence intervals (CIs) for inflammatory biomarker follow-up levels between intervention and control groups. - Results - Meta-analysis of eight RCTs (total of 592 patients with cancer or pre-cancerous conditions) showed that VID3S significantly lowered levels of serum tumor necrosis factor (TNF)-α (SMD [95%CI]: −1.65 [−3.07; −0.24]). VID3S also resulted in statistically non-significantly lower serum levels of interleukin (IL)-6 (SMD [95%CI]: −0.83, [−1.78; 0.13]) and C-reactive protein (CRP) (SMD [95%CI]: −0.09, [−0.35; 0.16]), whereas IL-10 levels were unaltered (SMD [95%CI]: −0.00, [−0.50; 0.49]). - Conclusion - Our study shows evidence of a significant reduction of TNF-α levels by VID3S for patients with cancer or precancerous lesions. Patients with cancer or precancerous lesions may benefit from personalized VID3S in suppressing tumour-promoting inflammatory response. - Prospero registration number - CRD42022295694.
Item Description:Online verfügbar: 17. Mai 2023, Artikelversion: 14. Juni 2023
Gesehen am 01.08.2023
Physical Description:Online Resource
ISSN:1532-1983
DOI:10.1016/j.clnu.2023.05.009

Similar Items